Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting

Cynthia Aristei*, Yasemin Bölükbaşı, Orit Kaidar-Person, Raphael Pfeffer, Meritxell Arenas, Liesbeth J. Boersma, Antonella Ciabattoni, Charlotte E. Coles, Pierfrancesco Franco, Marco Krengli, Maria Cristina Leonardi, Fabio Marazzi, Valeria Masiello, Icro Meattini, Angel Montero, Birgitte Offersen, Maria Lurdes Trigo, Céline Bourgier, Domenico Genovesi, Vassilis KoulouliasAlessio G. Morganti, Bruno Meduri, Nadia Pasinetti, Sara Pedretti, Elisabetta Perrucci, Sofia Rivera, Vincenzo Tombolini, Cristiana Vidali, Vincenzo Valentini, Philip Poortmans

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

We report on the third Assisi Think Tank Meeting (ATTM) on breast cancer, a brainstorming project which involved European radiation and clinical oncologists who were dedicated to breast cancer research and treatment. Held on February 2020, the ATTM aimed at identifying key clinical questions in current clinical practice and “grey” areas requiring research to improve management and outcomes. Before the meeting, three key topics were selected: 1) managing patients with frailty due to either age and/or multi-morbidity; 2) stereotactic radiation therapy and systemic therapy in the management of oligometastatic disease; 3) contralateral breast tumour prevention in BCRA-mutated patients. Clinical practice in these areas was investigated by means of an online questionnaire. In the lapse period between the survey and the meeting, the working groups reviewed data, on-going studies and the clinical challenges which were then discussed in-depth and subjected to intense brainstorming during the meeting; research protocols were also proposed. Methodology, outcome of discussions, conclusions and study proposals are summarized in the present paper. In conclusion, this report presents an in-depth analysis of the state of the art, grey areas and controversies in breast cancer radiation therapy and discusses how to confront them in the absence of evidence-based data to guide clinical decision-making.

Original languageEnglish
Article number103774
JournalCritical Reviews in Oncology/Hematology
Volume177
DOIs
StatePublished - Sep 2022
Externally publishedYes

Funding

FundersFunder number
Eli Lilly and Company
Pfizer
Novartis
Roche

    Keywords

    • BCRA-mutated patients
    • Breast cancer
    • Contralateral breast cancer prevention
    • De-escalating therapy
    • Oligometastatic disease
    • Radiation therapy
    • Stereotactic radiation therapy

    Fingerprint

    Dive into the research topics of 'Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting'. Together they form a unique fingerprint.

    Cite this